RedShiftBio at the OPT Congress: Oligonucleotide & mRNA Therapeutics 2025
Welcome to OPT Congress: Oligonucleotides & mRNA Therapeutics
OPT Congress is the premier event for scientists and executive directors involved in discovering and developing oligonucleotide and mRNA therapeutics. For 2025, we are delighted to expand our content and offer a conference program dedicated to emerging oligo modalities, sharing cutting-edge research and technologies used in designing new targeted therapies.
Now in its 10th year, this unique event brings together leading chemists, biologists, toxicologists, CMC experts, regulatory specialists, and technology providers like RedShiftBio to discuss advances in next-generation therapeutics. RedShiftBio’s innovative analytical solutions are helping to shape the future of biotherapeutic design, and we’re proud to highlight their contributions throughout the program.
In addition to 2 days of inspiring keynotes, breakout discussions, and 95+ scientific presentations, we deliver two in-depth short courses to further enhance learning opportunities. Don’t miss the chance to connect with industry leaders, including RedShiftBio, at this community-focused event offering robust and customizable programming tailored to your specific needs.
Event Date:
Add to your Calendar:
Request a Demo Today!
MMS offers unparalleled efficiency in bioprocess analytics, allowing for real-time protein concentration monitoring and minimizing workflow disruptions. This provides researchers and biopharmaceutical manufacturers with faster, more reliable structural insights to optimize formulation and stability studies.
Additional Events
